Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Clin Transl Oncol ; 14(5): 391-5, 2012 May.
Article de Anglais | MEDLINE | ID: mdl-22551547

RÉSUMÉ

PURPOSE: To analyse the outcome of adjuvant chemoradiotherapy for periampullary adenocarcinoma and the impact of tumour location as a prognosticator. METHODS AND MATERIALS: Between January 1991 and December 2002, 147 patients with periampullary cancer underwent adjuvant chemoradiotherapy after pancreaticoduodenectomy. Postoperative radiotherapy was delivered to tumour bed and regional lymph nodes up to 40 Gy at 2 Gy/fraction with a two-week planned rest. Intravenous 5-fluorouracil (500 mg/m(2)/day) was given on days 1-3 of each split course. The median follow-up period was 82 months in survivors. RESULTS: Tumour >2 cm and margin-positivity were more common in patients with pancreatic cancer than nonpancreatic periampullary cancers (p<0.0001 and 0.0780, respectively). According to the tumour location, 5-year overall survival rates of ampulla of Vater, distal common bile duct, duodenal and pancreatic head cancers were 53.0%, 50.3%, 37.5%, and 13.0%, respectively (p<0.0001). On multivariate analysis, pancreatic location (p<0.0001) and nodal involvement (p=0.0123) were associated with inferior overall survival. CONCLUSION: Regardless of its advanced histologic features, pancreatic location itself was an adverse prognostic factor affecting overall survival.


Sujet(s)
Adénocarcinome/anatomopathologie , Ampoule hépatopancréatique/anatomopathologie , Chimioradiothérapie adjuvante , Tumeurs du cholédoque/anatomopathologie , Tumeurs du duodénum/anatomopathologie , Fluorouracil/usage thérapeutique , Tumeurs du pancréas/anatomopathologie , Adénocarcinome/mortalité , Adénocarcinome/thérapie , Adulte , Sujet âgé , Antimétabolites antinéoplasiques/usage thérapeutique , Traitement médicamenteux adjuvant , Tumeurs du cholédoque/mortalité , Tumeurs du cholédoque/thérapie , Tumeurs du duodénum/mortalité , Tumeurs du duodénum/thérapie , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Tumeurs du pancréas/mortalité , Tumeurs du pancréas/thérapie , Pronostic , Radiothérapie adjuvante , Études rétrospectives , Taux de survie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE